/assets/production/practices/84c667cd75c703cfc49e2c00a43155eab79bfbef/images/2756783.jpg)
Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Check the skin
In one study, the average weight loss for patients taking tirzepatide was 52 pounds
Poll suggests millions want access to GLP1 drugs but are blocked by cost and limited coverage Roughly three million Canadian adults are now taking GLP-1 drugs, such as Ozempic and Mounjaro, with another two million saying they would like to but are held back by cost and coverage
Beyond that, the head-to-head study against tirzepatide and the REDEFINE 3 cardiovascular trial are both ongoing and expected to deliver readouts through 2026 and 2027
US$ 29.80
US$ 20.46
US$ 26.87
US$ 27.97
US$ 23.85
